Impact of personal protective equipment on the clarity of vision among trachoma survey graders and trichiasis surgeons in the context of COVID-19

Background/aimsThe COVID-19 pandemic necessitated the use of personal protective equipment for those involved in trachoma survey grading and trichiasis surgery. We sought to determine which configuration of a face shield would be less likely to impact grading accuracy and ability to conduct trichiasis surgery. The research also included assessment of comfort, ease of cleaning and robustness.MethodsThere were three research phases. In phase 1, assessment of four potential face shield configurations was undertaken with principal trachoma graders and trichiasis surgeon trainers to decide which two options should undergo further testing. In phase 2, clarity of vision and comfort (in a classroom environment) of the two configurations were assessed compared with no face shield (control), while grading trachomatous inflammation—follicular (TF). The second phase also included the assessment of impact of the configurations while performing trichiasis surgery using a training model. In phase 3, face shield ease of use was evaluated during routine surgical programmes.ResultsIn phase 2, 124 trachoma graders and 28 trichiasis surgeons evaluated the 2 face shield configurations selected in phase 1. TF agreement was high (kappa=0.83 and 0.82) for both configurations compared with not wearing a face shield. Comfort was reported as good by 51% and 32% of graders using the two configurations. Trichiasis skill scores were similar for both configurations.ConclusionThe face shield configuration that includes a cut-out for mounting the 2.5× magnifying loupes does not appear to impact the ability or comfort of trachoma graders or trichiasis surgeons to carry out their work.

Late PAMM-Like Lesions in a Patient with HIV Retinopathy

This report describes a case of a newly diagnosed 49-year-old HIV patient, who presented with decreased visual acuity and retinal lesions characterized by ischemia at the level of the deep retinal capillary plexus, documented with optical coherence tomography (OCT), OCT angiography, fluorescein angiography, and visual fields testing. These lesions closely resembled the morphologic and clinical characteristics of late paracentral acute middle maculopathy. The presence of these lesions suggests that HIV microangiopathy can potentially affect both superficial and deep retinal capillary plexuses.

How to Face COVID-19 in Ophthalmology Practice

Background: The novel coronavirus pneumonia has attracted considerable attention from the international community. With the spread of outbreaks around the world, the WHO characterized COVID-19 as a pandemic.Methods: Relevant studies in PubMed were searched from January 1, 2020 to April 12, 2020, using the following search strategy: ("novel coronavirus pneumonia” OR "severe acute respiratory syndrome coronavirus 2” OR "coronavirus disease 2019” OR "COVID-19” OR "novel coronavirus neumonia”) AND ("ophthalmology” OR "ophthalmologist” OR "eye” OR "conjunctiva” OR "conjunctivitis” OR "corneal” OR "keratitis”).Results: SARS-CoV-2 can spread through aerosol and is detected in tears of patients with COVID-19 infection. Notably, some infected patients had conjunctivitis, and conjunctivitis was the first symptom in some patients later diagnosed to have COVID-19 infection. This would increase the risk for ophthalmologists through inpatient consultations or regular clinical practice. When dealing with seemingly regular ophthalmic patients, the vigilance of ophthalmologists and associated staff tends to be reduced.Conclusion: Ophthalmologists must continuously update their knowledge regarding COVID-19 and take effective measures to prevent COVID-19 transmission.

Acute and sub-acute ocular manifestations in pediatric patients with COVID-19: A systematic review

Background: The coronavirus disease 2019 (COVID-19) pandemic has been the most challenging health problem in the last 2 years. Post-COVID-19 multisystem inflammatory syndrome of children (MIS-C) is a severe post-COVID-19 complication in pediatric patients. Ocular manifestations may be the first presentation of MIS-C, wherein prompt treatment may improve outcomes. In this systematic review, we aimed to summarize the acute and sub-acute ocular manifestations in pediatric patients with laboratory-confirmed COVID-19.Methods: We included all online primary studies, with no language restriction and published between January 1, 2019 and November 18, 2020, reporting any acute or sub-acute ocular manifestations in children with laboratory-confirmed COVID-19. PubMed/MEDLINE was searched using the following MeSH and Emtree terms: "eye,” "ophthalmologic,” "ocular,” "vision,” "conjunctivitis,” "severe acute respiratory syndrome coronavirus 2,” "SARS-CoV-2,” "corona,” "2019-nCoV,” "COVID19,” and "COVID.” The eligibility and quality of the selected records were assessed by two independent reviewers as per the Cochrane Handbook for Systematic Review.Results: A total of 1,192 records were identified electronically. Seven papers were extracted from the reference lists of the eligible records. Thirty-six papers met the inclusion criteria and were categorized into two subgroups according to acute or sub-acute presentation of ocular manifestations. Among 463 pediatric patients with COVID-19, 72 (15.5%) had acute ocular manifestations. There was one patient with central retinal vein occlusion and another with photophobia and diplopia associated with meningoencephalitis. Among 895 pediatric patients with post-COVID-19 MIS-C, 469 (52.4%) had ocular manifestations, which only included non-purulent conjunctivitis.Conclusions: Ocular manifestations have been reported in less than one-fifth of pediatric patients with acute COVID-19. Furthermore, conjunctivitis was the only ocular manifestation reported in half of the patients with MIS-C, and it may be missed easily due to its non-purulent nature. During the COVID-19 pandemic, pediatricians and health workers must remain vigilant for early detection of signs of this potentially fatal post-COVID-19 inflammatory syndrome.

COVID-19: Preliminary Clinical Guidelines for Ophthalmology Practices

The zoonotic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its resultant human coronavirus disease (COVID-19) recently appeared as a global health threat that can cause severe respiratory infection and terminal respiratory distress. By the first week of April, more than 1.3 million people had been globally infected and more than 70,000 had lost their lives to this contagious virus. Clinical manifestations occur shortly after exposure, or a few days later. There is controversy regarding the transmission of the virus through the tear and conjunctiva;however, there are reports that the ocular surface might be a potential target for COVID-19. The ease of transmission of this virus at close proximity presents a risk to eyecare workers. Several recommendations have been issued by local and national organizations to address the issue of safe ophthalmic practice during the ongoing COVID-19 pandemic. These guidelines have numerous similarities;however, subtle differences exist. The purpose of this paper was to discuss measures, with a specific focus on standard precautions, to prevent further dissemination of COVID-19 at Eye Clinics. We have proposed procedures to triage suspected cases of COVID-19, considering emergency conditions.

Posterior segment manifestations and imaging features post-COVID-19

Background: To report the posterior segment (uvea and retinal) manifestations and imaging characteristics of eyes of patients with and after coronavirus disease 2019 (COVID-19).Methods: We searched the PubMed/MEDLINE database to identify relevant articles using the following search terms: COVID-19, SARS-CoV-2, retina, uvea, optic nerve, retinal findings, posterior segment manifestations, and endophthalmitis. Articles published from December 1, 2019, to May 30, 2021, and indexed in PubMed/MEDLINE were screened.Results: For the purpose of this review, we included clinical features of 26 case reports and 8 case series. The posterior segment manifestations reported included cotton wool spots, retinal hemorrhages, central serous retinopathy, papillophlebitis, optic neuritis, panuveitis, multifocal retinitis, necrotizing retinitis, central retinal artery/vein occlusion, and Purtschner like retinopathy. In this review, we have also included optical coherence tomography angiography (OCTA) features that have been described in COVID-19 patients with pneumonia.Conclusions: COVID-19 patients can experience uveo-retinal manifestations even after recovery. These patients, even if asymptomatic for eye symptoms, should undergo an eye evaluation to rule out posterior segment involvement. OCTA performed in these patients revealed microvascular changes in the superficial and deep retinal plexuses. Some of these patients may require anticoagulant or antiplatelet therapy.

COVID‐19 vaccination and vision loss in three older male individuals homoplasmic for m.14484T>C mutation in the ND6 gene

Purpose: To report three older male individuals, all homoplasmic for m.14484 T > C mutation in the ND6 gene, presenting onset of vision loss weeks‐months after covid vaccination. None reported a history of covid‐19 infection.Methods: All clinical data was extracted and reported here as a Case Series.Results: A 68 years old man (A) had a 3rd dose of BioNTech/Pfizer COVID‐19 vaccination on 1st Nov 2021. 10 days later his vision was 6/6 OD and 6/60 OS. By Dec 2021 VA was 6/36 OD and 6/60 OS. His nephew lost vision age of 18 years with LHON. In March 2022, visual acuities were HM OD and HM OS. In May 2022 visual acuity was HM OD, PL OS. He started on idebenone 300 mg tds.A 55 years old man (B) had a 1st dose Astra Zeneca COVID‐19 vaccination in mid Feb 2021. 12 days later, March 2021 he developed a Bell's Palsy and sensory neuropathy at the top of his legs, feet and upper arms, with difficulty walking. MRI showed enhanced optic nerves and enhanced lesions at C2. In April 2021, he lost vision in his right eye, followed by left eye in June 2021. By September 2021 vision was CF BEs. He started on idebenone 300 mg po tds. In May 2022 he was LogMAR @ 2 m 1.34 OD and MH OS.A 72 years old man (C) had his 2nd dose of BioNTech/Pfizer COVID‐19 vaccination in April 2021. In Sept 2021 he reported loss of vision in both eyes but could not date onset. He was the maternal cousin of individual B. In May 2022 vision was 3/60 OD CF OS. He started on idebenone 300 mg po tds.Conclusions: Adverse ocular events related to COVID‐19 vaccines are remarkable rare. There are >20 published case reports (~89 patients) of adverse ocular events within 28 days of COVID‐19 vaccination, with all three vaccines (Pfizer, AstraZeneca and Moderna). Reports incl. conjunctivitis, facial and abducens nerve palsy, CSR, uveitis, MEWDS, VKH, Graves' Disease, endothelial graft rejection, AAION and AZOOR. The role of vaccination in subsequent vision loss in those with underlying mitochondrial mutation is not clear.

What has COVID taught us about glaucoma management?

Since the spread of coronavirus pandemic caused by the SARS‐CoV‐2 virus, several measures were implemented worldwide to try to stop the pandemic and minimize its impact on healthcare.Ophthalmologists are one of the most exposed specialists to airborne particles due to their close proximity to patients' faces during the examination.Therefore during the pandemic, all non‐essential procedures and appointments were cancelled or postponed, and new approaches to virtual clinics were explored.This presentation will discuss the impact of Covid related delayed care in patients with glaucoma and how the implementation of virtual and diagnostic clinics had on reducing long waiting list and streamlining patient's care .

Patterns of sclero‐uveitis in a referral center in Tunisia, North Africa

Purpose: To describe the demographics and clinical characteristics of anterior scleritis associated with uveitis in a referral center in Tunisia.Methods: The charts of twenty patients (20 eyes) diagnosed with sclero‐uveitis at Fattouma Bourguiba University Hospital, Monastir, Tunisia, presented between January 2015 and April 2022, were retrospectively reviewed. Detailed ophthalmic examination and fundus photography were performed in all patients. Mean follow‐up period was 28.4 months. Patients with keratitis or posterior scleritis were excluded.Results: There were eight women and 12 males patients with a mean age of 34.8 years. All patients presented with ocular pain. Mean initial best‐corrected visual acuity (BCVA) was 20/80 (range, 20/2000–20/25).There was an associated anterior uveitis in 80% of cases and panuveitis in 20%. Clinical findings at presentation included nodular scleritis in five eyes (25%) and scleromalacia perforans in four eyes (20%). Idiopathic sclero‐uveitis accounted for almost 55%. Identified causes of sclerouveitis included rheumatoid arthritis in four eyes (20%), tuberculosis in three eyes (15%), granulomatosis with polyangiitis in two eyes (10%), sarcoidosis in one eye (5%) and then one case after mRNA 1273 vaccine (5%). Ocular complications included pupillary seclusion in 25% of cases and vision loss in 10% of patients. Mean final BCVA was 20/100 (range, 20/4000–20/32). Treatment modalities of non‐infectious scleritis included indomethacine in 14 patients (82.3%), systemic corticosteroid in seven patients (41.1%) and immunosuppressant or biological agent in five patients (29.4%).Conclusions: Our results provide useful information about the patterns and etiologies of sclerouveitis. The leading causes of sclerouveitis include mainly rheumatoid arthritis and tuberculosis. An infectious cause should be always ruled out.

Retinal blood flow and oxygen saturation in patients previously infected with COVID‐19

Purpose: The SARS‐CoV‐2 pandemic has affected all countries in the world and is still ongoing. Although respiratory symptoms are the main manifestation of acute infection, there is also increasing evidence that neurological and vascular symptoms occur, and it is unknown whether residuals remain after patients have recovered. We therefore set out to investigate whether ocular vascular alterations remain after patients have recovered.Methods: Patients that had recovered from COVID‐19 infection within the last 6 months before inclusion and healthy age‐ and sex‐matched controls were recruited. Main inclusion criteria for patients were confirmed positive PCR test for SARS‐CoV‐2 in the medical history and positive testing for SARS‐CoV‐2 seroprevalence while controls had no history of COVID‐19 infection. Arteriovenous (AV) difference in oxygen saturation was calculated out of retinal arterial and venous oxygen saturation, which were measured with a commercially available Dynamic Vessel Analyser (DVA, Imedos, Germany). Retinal vessel diameters and arteriovenous ratio (AVR) were assessed using the same device. In addition, mean blur rate in the tissue area of the optic nerve head (MT) was quantified using laser speckle flowgraphy (LSFG, Nidek, Japan).Results: 29 patients that had recovered from moderate to severe COVID‐19 requiring hospitalization (mean age 35 ± 17 years) and 11 control subjects (mean age 36 ± 12 years) were included in the present study. No differences between groups regarding sex or concomitant diseases in the medical history were found. Body mass index (BMI) was significantly higher in patients that had recovered from COVID‐19 (27.5 ± 5.6 vs. 24.5 ± 2.8 m2/kg, p = 0.036). AVR as well as AV difference in oxygen saturation was significantly lower in patients compared to healthy controls (p = 0.021 for AVR and p = 0.023 for AV difference in oxygen saturation). MT in the optic nerve head also was significantly lower in patients (23.4 ± 10.1 a.u.) than in control subjects (47.3 ± 26.6 a.u., p < 0.001).Conclusions: The results of this study imply that retinal metabolism is still altered in patients after recovering from COVID‐19 infection. Longitudinal studies are required to investigate whether these changes in retinal vessels as well as optic nerve head blood flow are temporary or remain.

Ocular Therapeutics for Optometry in Africa

While optometrists should not abandon their traditional strengths such as the provision of spectacle lenses and contact lens practice, there is an urgent need to improve access to more affordable and qualitatively satisfactory eye and vision care for not only relatively uncomplicated ocular refractive services but also regarding various ophthalmic disorders such as ocular surface disorders, milder and often self-limiting ophthalmic infections and glaucoma. The same weaknesses in the satisfactory provision of more comprehensive eye care in South Africa also extend to other parts of Africa where eye care services (including also low or partial vision and contact lenses for conditions such as keratoconus) are frequently constrained and patients with relatively minor but sometimes more serious eye problems are largely underserved because of inadequate utilisation of existing infrastructure and personnel or, in many cases, severe lack of necessary infrastructure and personnel in ophthalmology and optometry. [...]to the readers of the journal and everyone else involved in whatever capacity with the journal, all the very best and hopefully 2023 will bring many good things as we emerge from the shadow of the COVID-19 pandemic!

Pseudomembranous Conjunctivitis following Exposure to Arisaema ringens Sap: A Case Report

Plants of the Araceae family exude a sap containing calcium oxalate, a toxic substance that causes dermatitis. However, ocular injury due to exposure to Araceae sap has rarely been reported. Herein, we present a case of severe pseudomembranous conjunctivitis following exposure to Arisaema ringens, an Araceae species and popular houseplant in Japan. A 67-year-old man presented with pain in his right eye after exposure to the sap of A. ringens. At presentation, the best corrected visual acuity and intraocular pressure in the right eye were 20/800 and 15 mm Hg. Slit-lamp examination showed strong hyperemia, conjunctival chemosis, and corneal edema with many pseudomembranes, and fluorescein staining revealed corneal epithelial defects in the central area of the cornea. We washed the ocular surface with saline and initiated treatment with topical instillations of 1.5% levofloxacin and 0.1% betamethasone, combined with ofloxacin eye ointment. After repeatedly removing the pseudomembranes and increasing the frequency of the topical instillations, pseudomembranous conjunctivitis and corneal erosion gradually improved. One week following the injury, the corneal epithelial defects were no longer detectable, and the patient’s best corrected visual acuity recovered to 20/25. It is important for ophthalmologists and primary care physicians to be aware of the ocular toxicity of A. ringens and should counsel their patients accordingly. Moreover, preventative measures, such as the use of protective eyewear, should be taken when cutting this houseplant.

Efficacy and safety of hyperbaric oxygen therapy for acute central retinal artery occlusion in Hong Kong: results of the first 3 years

Purpose: To review the efficacy and safety of hyperbaric oxygen therapy (HBOT) for central retinal artery occlusion (CRAO) in Hong Kong patients. Methods: Patients diagnosed with CRAO with symptom onset ≤6 hours who failed emergency bedside ocular treatment were referred to a course of HBOT. Changes in best corrected visual acuity (VA) after HBOT and adverse effects and complications of HBOT were recorded. Changes in best corrected VA between the pre-COVID-19 group and the COVID-19-pandemic group were compared. Results: 34 men and 26 women with CRAO aged 27 to 89 years were included for analysis. The mean follow-up period was 169±226 days. The mean number of HBOT sessions received was 8.6±3.2. The mean best corrected VA improved from 2.02±0.36 to 1.53±0.61 logMAR after HBOT (p<0.00001). 65% of patients had improvement and 33.3% had no improvement. VA changes between the pre-COVID-19 group (n=22) and COVID-19-pandemic group (n=38) were comparable (-0.53±0.58 vs -0.46±0.57 logMAR, p=0.59), despite a delay in hospital attendance. 41.7% of patients failed to equalize the pressure during treatment requiring myringotomy or even grommet insertion. 20% of patients had barotrauma. Other adverse events included convulsion, confusion, sinus pain, and hypoglycemia. Conclusion: In patients with CRAO, HBOT is effective in improving best corrected VA, even during the COVID-19 pandemic.

Preventive measures for lacrimal procedures during the outbreak of COVID-19: perspective

Aerosols are a major route of transmission of COVID-19. Lacrimal procedures such as lacrimal irrigation, manipulation, and surgery involve aerosols. We searched the PubMed database for articles related to preventive measures of lacrimal procedures during the COVID-19 pandemic. Seven relevant articles were reviewed. Preoperative measures include patient screening, triage, and use of personal protective equipment. Intraoperative measures include procedure-specific aerosol reduction, use of povidone-iodine as disinfectant, and use of personal protective equipment. Postoperative measures include use of telemedicine for follow-up. Elective lacrimal procedures were suspended periodically and resumed when the outbreak subsided, with strict implementation of guidelines. The preventive measures may be effective in lowering the risk of transmission from patients potentially positive with COVID-19.

Highlights from this issue

Economic, clinical and social impact of simple limbal epithelial transplantation for limbal stem cell deficiency (see page 923) A comprehensive literature survey, questionnaire-based survey and economic analysis indicates that simple limbal epithelial transplantation is a better alternative to cultivated limbal epithelial transplantation in terms of anatomical success, cost and accessibility. Association between body mass index and diabetic retinopathy in Asians: the Asian eye epidemiology Consortium (AEEC) study (see page 980) In a pooled analysis including 10 010 Asian adults with diabetes from 12 cross-sectional studies across six Asian countries, obesity was inversely associated with both any diabetic retinopathy and vision-threatening diabetic retinopathy, independent of potential risk factors. Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy (see page 987) We report the results of a novel personalised anti-vascular endothelial growth factor monotherapy regimen for the management of polypoidal choroidal vasculopathy which achieves comparable outcomes to a fixed 8-weekly regimen and high polypoidal lesion closure rate.

Personalised model to predict keratoconus progression from demographic, topographic and genetic data

*Correspondence – Olivia Li: o.li@nhs.netTo generate a personalised prognostic model to predict keratoconus progression to corneal collagen cross-linking (CXL).Methods and AnalysisIn this retrospective cohort study, we recruited 5,025 patients (9,341 eyes) with early keratoconus between January 2011 and November 2020. Genetic data from 926 patients was available. We evaluated both change in keratometry or CXL as indices of progression and used the Royston-Parmar method on the proportional hazards scale to generate a prognostic model. We calculated hazard ratios (HR) for each significant covariate, with explained variation and discrimination.ResultsAfter exclusions, model-fitting comprised 8,701 eyes, of which 3,232 underwent CXL. For early keratoconus CXL provided a more robust prognostic model than keratometric progression. The final model explains 33% of the variation in time-to-event age HR [95% confidence limits] 0.9 [0.90–0.91], maximum anterior keratometry (Kmax) 1.08 [1.07–1.09], and minimum corneal thickness 0.95 [0.93–0.96] as significant covariates. Single nucleotide polymorphisms (SNPs) associated with keratoconus (n=28) did not significantly contribute to the model. The predicted time-to-event curves closely followed the observed curves during internal-external validation.ConclusionsA prognostic model to predict keratoconus progression could aid patient empowerment, triage and service provision. Age at presentation is the most significant predictor of progression risk. Candidate SNPs associated with keratoconus do not contribute to progression risk.